Drug profile

The FDA adverse-event record for Feline Leukemia Virus, Kawakami-Theilen, Kv

62 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Feline Leukemia Virus, Kawakami-Theilen, Kv. See the species affected, top reactions, and outcomes below.

62
adverse-event reports
21.0%
death-coded share
Cat
most-reported species
37
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
62
Total Reports
13
Deaths Reported
21.0%
Death Rate

Active Ingredients

Feline Leukemia Virus, Kawakami-Theilen, Kv

Administration Routes

Subcutaneous

Species Affected

Cat 62

Most Affected Breeds

Domestic Shorthair 49
Domestic Longhair 5
Siamese 3
Ragdoll 2
Domestic Mediumhair 1
Norwegian Forest 1
Maine Coon 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 37
Fever 24
Anorexia 20
Other abnormal test result NOS 12
Weight loss 11
Dehydration 10
Vomiting 9
Anaemia NOS 9
Leucocytosis NOS 8
Death by euthanasia 8
Adipsia 7
Elevated total bilirubin 6

Outcome Breakdown

Ongoing
29 (46.8%)
Recovered/Normal
16 (25.8%)
Euthanized
8 (12.9%)
Died
5 (8.1%)
Outcome Unknown
4 (6.5%)

Feline Leukemia Virus, Kawakami-Theilen, Kv Adverse Event Insights

62 reports name Feline Leukemia Virus, Kawakami-Theilen, Kv; 13 recorded a death outcome (21.0% of reported events, not a population-level mortality rate). Active ingredient: Feline Leukemia Virus, Kawakami-Theilen, Kv. Administration route: Subcutaneous.

By species: Cat (62 reports). By breed: Domestic Shorthair (49), Domestic Longhair (5), Siamese (3).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (37), Fever (24), Anorexia (20), Other abnormal test result NOS (12). Outcome, 62 coded reports: Ongoing leads at 46.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.